Physician profile
Eric M Lehman
NPI 1689611618
$6,659.59
in general payments reported to CMS, 2019-2025
21 companies · $79.98 in 2025
The $79.98 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $243 · 2021: $1,109 · 2022: $1,275 · 2023: $1,632 · 2024: $1,893 · 2025: $79.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,494 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,494.34 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,210.20 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $979.78 | 2020-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $878.38 | 2020-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $757.87 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $503.69 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $489.39 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $388.56 | 2019-2024 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $373.03 | 2021-2024 | Fanapt |
| Sunovion Pharmaceuticals INC. | $262.61 | 2019-2022 | |
| Lundbeck LLC | $157.47 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $130.29 | 2023-2024 | Auvelity |
| Indivior INC. | $118.60 | 2022-2023 | Perseris |
| Neuronetics, INC. | $118.06 | 2019 | |
| Ironshore Pharmaceuticals INC. | $67.65 | 2021-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $55.93 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.79 | 2024 | |
| Almatica Pharma LLC | $36.93 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Ethicon US, LLC | $27.83 | 2025 | Echelon Endopath |
| Corium, LLC | $24.08 | 2021 | |
| Allergan, INC. | $20.19 | 2020 | |
| Revance Therapeutics, INC. | $17.26 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.